Esketamine for major depressive disorder: pharmacokinetics and toxicological considerations
Shreya Vasudeva, Gabrielle F. M. Lovell, Joshua Daniel Rosenblat
Expert Opinion on Drug Metabolism & Toxicology May 4, 2026 DOI: 10.1080/17425255.2026.2671066 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression Esketamine |
Abstract
1. Esketamine nasal spray was FDA-approved in 2019 for treatment-resistant depression (TRD; in conjunction with an oral antidepressant), with approval expanded to major depressive disorder (MDD) wi...
Citations in the library
Cites 10
- Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings) CNS Neuroscience & Therapeutics April 10, 2013
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders JAMA Psychiatry March 1, 2017
- Ketamine for the treatment of major depression: a systematic review and meta-analysis EClinicalMedicine August 1, 2023
- The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. Neuroscience & Biobehavioral Reviews November 23, 2020
- The abuse liability of ketamine: A scoping review of preclinical and clinical studies. Journal of Psychiatric Research May 1, 2022
and 5 more in the library